Onclive Team

The annual cost of new oncology drugs will continue to trend upward over the next 5 years, eventually breaching the $200,000 level.

The Association of Community Cancer Center's 45th Annual Meeting and Cancer Center Business Summit prepares oncology stakeholders for dramatic transformations in cancer care delivery.

More than 90% of older patients with relapsed/refractory acute myeloid leukemia had successful engraftment of allogeneic hematopoietic stem cell transplant preceded by novel conditioning with an iodinated CD45-targeted antibody.

Chimeric antigen receptor T cells targeting CD30 proved to be safe and active in relapsed/refractory Hodgkin lymphoma.

Two doses of adjuvanted recombinant zoster vaccine following autologous hematopoietic stem cell transplant led to rapid and durable cell-mediated immune responses, results from a subgroup analysis of a large randomized, placebo-controlled trial showed.1

Transplant-associated thrombotic microangiopathy occurred in as many as 36% of hematopoietic cell transplants and significantly increased the risk of transplant-related mortality.

Patients with relapsed/refractory chronic lymphocytic leukemia had an improved response rate with chimeric antigen receptor T-cell therapy if they also received ibrutinib.

An international leader in finding new, innovative treatments for lymphoma patients, City of Hope announced today that it has received its third lymphoma Specialized Programs of Research Excellence grant from the National Cancer Institute.

Adults with acute lymphoblastic leukemia had worse outcomes, including lower survival, after myeloablative allogeneic transplantation if they remained positive for minimal residual disease at the time of transplant.

Cleveland Clinic research has found that the blood thinner rivaroxaban significantly reduces venous thromboembolism (VTE)—a blood clot in the venous system—and VTE-related death for outpatient, high-risk cancer patients while they are taking the oral anticoagulant.

We traveled to Memphis, Tennessee for a State of the Science Summit™ on Genitourinary Cancers, which focused on advances made in the treatment landscapes of metastatic renal cell carcinoma and prostate cancer.

New options for patients with hematologic malignancies stemming from recent FDA approvals are making an impact on treatment strategies recommended in the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology.

We traveled to New York, New York, for a State of the Science Summit™ on Advanced Non–Small Cell Lung Cancer, which focused on topics ranging from surgical techniques, to headway made in immunotherapy, to emerging biomarkers, to diagnostic advancements.

We traveled to Minneapolis, Minnesota, for a State of the Science Summit on Breast Cancer, which focused on surgical approaches for node-positive breast cancer, the use of CDK4/6 inhibitors in hormone receptor–positive disease, and emerging drug therapies in triple-negative disease.

In a pair of new studies, researchers from Roswell Park Comprehensive Cancer Center outline strategies for overcoming pancreatic cancer’s resistance to treatment through approaches that exploit this cancer’s reliance on uncontrolled, or deregulated, cell proliferation.

John Theurer Cancer Center at Hackensack Meridian Health Hackensack University Medical Center announced that it is leading enrollment worldwide for WIZARD 201G, a global Phase 2 study in glioblastoma.

We traveled to Syracuse, New York, for a State of the Science Summit on Advanced Non–Small Cell Lung Cancer, which focused on practice-change clinical trials in the space, as well as novel approaches to treatment with checkpoint inhibitors, targeted therapies, radiation, and minimally invasive surgery.

The National Pancreas Foundation (NPF) has designated Roswell Park Comprehensive Cancer Center as an NPF Center for pancreatic cancer.

Dana-Farber Cancer Institute researchers are Grand Challenge winners for a project that aims to discover how certain microbes inside the body lead to colorectal cancer and influence a patient’s response to treatment.

We traveled to New York City, New York, for a State of the Science Summit on Multiple Myeloma, which focused on stem cell transplant, minimal residual disease, maintenance options, and treatment approaches for newly diagnosed myeloma.

Despite changes affecting how oncologists prescribe and manage opioid use among their patients, there are few data analyzing the frequency and extent to which patients with cancer die of opioid overdoses.

Patients with previously untreated hepatocellular carcinoma lived twice as long if they responded to TKI therapy as compared with patients who did not achieve an objective response.

The PD-L1 inhibitor durvalumab achieved objective responses in about a fourth of patients with microsatellite instability-high advanced solid tumors, including colorectal cancer.

Overall survival in metastatic gastric/gastroesophageal junction cancer improved significantly in patients who received the combination therapy TAS-102, irrespective of prior gastrectomy.

Two-thirds of patients with untreated metastatic HER2-positive esophagogastric adenocarcinoma remained free of disease progression at 6 months with a combination of pembrolizumab, trastuzumab, and chemotherapy.

The Association of Community Cancer Centers ninth annual Trending Now in Cancer Care survey reveals how cancer programs across the country are being impacted by pressure from turbulence in multiple sectors: payers, government, and industry.

We traveled to Washington D.C. for a State of the Science Summit on Breast Cancer, which focused on additional recent advances in the NSCLC and small cell lung cancer paradigms, touching on TKIs, immunotherapy, and other investigational agents.

Over the past 2 decades, considerable efforts have focused on the development of therapies that can restore apoptosis in malignant cells.

Aaron R. Hansen, BSc, MBBS, discusses progress with costimulatory immune checkpoints in oncology.

The understanding of the BCL2 oncogene and the BCL-2 protein family have motivated the current advancements in cancer therapeutics that target different members of apoptotic regulatory networks.